Back

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.

23 May 2023 (10:02 - 10:10)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jasper Tromp

National University Health System, Singapore (Singapore)

6 More presentations in this session

Presentation thumbnail
Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry
Doctor D. Stolfo (Udine, IT)
Abstract Slides Video
Presentation thumbnail
Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial
Doctor S. Chatur (Boston, US)
Abstract Slides Video
Presentation thumbnail
Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry
Doctor F. Guidetti (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure
Ms I. Beldhuis (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Impact of lower systolic blood pressure on efficacy and safety of sacubitri/valsartan compared to ramipril in patients with acute myocardial infarction: insights from PARADISE-MI trial
Doctor M. Senni (Bergamo, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy
Video

The Event

Event poster

Heart Failure 2023

23 May 2023 10:02 CET
You may be interested in
thumbnail
Congress Presentation
The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial
thumbnail
Congress Presentation
EMPULSE
thumbnail
Congress Presentation
Dapagliflozin in patients hospitalised with newly diagnosed heart failure: an analysis of the randomized DAPA ACT HF-TIMI 68 trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources